GlassScriptPhysician profile
Kathryn E Payson
NPI 1144356031
$1,464.81
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $677 · 2023: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $399.30 | 2021-2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.72 | 2021-2023 | Ofev |
| Amgen INC. | $189.92 | 2021-2023 | Tezspire |
| Pfizer INC. | $102.35 | 2021-2022 | |
| Mylan Specialty L.P. | $102.30 | 2021-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 | |
| Baxter Healthcare | $73.04 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $68.67 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.71 | 2022-2023 | Hyqvia |
| Glaxosmithkline, LLC. | $51.14 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Grifols USA, LLC | $24.28 | 2022 | |
| Genzyme Corporation | $22.87 | 2022 | |
| United Therapeutics Corporation | $21.55 | 2021 | |
| Mayne Pharma Commercial LLC | $18.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Payson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.